当前位置: X-MOL 学术Clin. Med. Insights Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Immunotherapy Induced Myasthenic-Like Syndrome in a Metastatic Melanoma Patient With Amyotrophic Lateral Sclerosis
Clinical Medicine Insights: Oncology ( IF 1.9 ) Pub Date : 2020-12-28 , DOI: 10.1177/1179554920978024
Muhammad Jaffer 1 , Matthew Chung 1, 2 , Esha Sharda 1 , Asha Ramsakal 1, 3 , Edwin Peguero 1, 3 , Neha Verma 1, 3 , Sepideh Mokhtari 1, 3
Affiliation  

Immunotherapy agents such as ipilimumab and nivolumab are immensely effective in the treatment of various malignancies. Despite this, neurologic immune-related sequelae (NIRS) have been observed. Prompt diagnosis and treatment is critical to improve patient outcomes. We present a case of a 63-year-old man with stage IV metastatic melanoma beginning treatment with ipilimumab and nivolumab. Gathered history from the patient showed that he had a 3-year presentation of bradykinesia, shuffling gait, and muscle cramping. After one dose, the patient began to have progressively worsening generalized weakness; after receiving the immunotherapy, there was a rapid decline in his health. In addition to weakness, the patient developed diplopia, impaired single breath count, lingual and upper/lower extremity fasciculations, and brisk reflexes. While the lumbar puncture and myasthenia panel were non-diagnostic, the electromyography (EMG) revealed axonal neuropathy and diffuse denervation/reinnervation changes. Furthermore, a magnetic resonance imaging (MRI) displayed fatty replacement of the tongue with a bright tongue sign. These results pointed to the diagnosis of amyotrophic lateral sclerosis (ALS) superimposed onto myasthenic-like syndrome. The patient was started on various treatments; however, unfortunately he died due to acute hypoxic respiratory failure. This case highlights important considerations that must be taken when using immunotherapy, especially in patients with pre-existing neurological deficits. Furthermore, it shows the importance of early diagnosis as treatment can potentially cure adverse sequelae.



中文翻译:

免疫疗法诱发肌萎缩性侧索硬化症的转移性黑素瘤患者的重症肌无力综合征

免疫治疗剂,例如ipilimumab和nivolumab在治疗各种恶性肿瘤方面极为有效。尽管如此,仍观察到神经系统免疫相关后遗症(NIRS)。及时诊断和治疗对于改善患者预后至关重要。我们介绍了一例63岁的IV期转移性黑色素瘤患者,开始使用ipilimumab和nivolumab治疗。收集的患者病史显示,他有3年的运动迟缓,步态蹒跚和肌肉痉挛的表现。一剂后,患者开始逐渐加重全身无力。接受免疫疗法后,他的健康迅速下降。除了虚弱外,患者还会出现复视,单呼吸计数受损,舌尖和上/下肢束缚和轻快反射。虽然无法诊断出腰穿和肌无力,但肌电图(EMG)揭示了轴突神经病和弥漫性神经支配/神经支配的改变。此外,磁共振成像(MRI)显示了舌头脂肪的替换,舌头明亮。这些结果表明,肌萎缩性侧索硬化症(ALS)叠加在肌无力样综合征上的诊断。患者开始接受各种治疗。然而,不幸的是他死于急性缺氧性呼吸衰竭。这种情况突出了使用免疫疗法时必须考虑的重要考虑因素,尤其是对于已有神经系统缺陷的患者。此外,它显示出早期诊断的重要性,因为治疗可以潜在地治愈不良后遗症。肌电图(EMG)显示轴突神经病和弥漫性神经支配/神经支配改变。此外,磁共振成像(MRI)显示了舌头脂肪的替换,舌头明亮。这些结果表明,肌萎缩性侧索硬化症(ALS)叠加在肌无力样综合征上的诊断。患者开始接受各种治疗。然而,不幸的是他死于急性缺氧性呼吸衰竭。这种情况突出了使用免疫疗法时必须考虑的重要考虑因素,尤其是对于已有神经系统缺陷的患者。此外,它显示出早期诊断的重要性,因为治疗可以潜在地治愈不良后遗症。肌电图(EMG)显示轴突神经病和弥漫性神经支配/神经支配改变。此外,磁共振成像(MRI)显示了舌头脂肪的替换,舌头明亮。这些结果表明,肌萎缩性侧索硬化症(ALS)叠加在肌无力样综合征上的诊断。患者开始接受各种治疗。然而,不幸的是他死于急性缺氧性呼吸衰竭。这种情况突出了使用免疫疗法时必须考虑的重要考虑因素,尤其是对于已有神经系统缺陷的患者。此外,它显示出早期诊断的重要性,因为治疗可以潜在地治愈不良后遗症。磁共振成像(MRI)显示舌头脂肪的替换为明亮的舌头征兆。这些结果表明,肌萎缩性侧索硬化症(ALS)叠加在肌无力样综合征上的诊断。患者开始接受各种治疗。然而,不幸的是他死于急性缺氧性呼吸衰竭。这种情况突出了使用免疫疗法时必须考虑的重要考虑因素,尤其是对于已有神经系统缺陷的患者。此外,它显示出早期诊断的重要性,因为治疗可以潜在地治愈不良后遗症。磁共振成像(MRI)显示舌头脂肪的替换为明亮的舌头征兆。这些结果表明,肌萎缩性侧索硬化症(ALS)叠加在肌无力样综合征上的诊断。患者开始接受各种治疗。然而,不幸的是他死于急性缺氧性呼吸衰竭。这种情况突出了使用免疫疗法时必须考虑的重要考虑因素,尤其是对于已有神经系统缺陷的患者。此外,它显示出早期诊断的重要性,因为治疗可以潜在地治愈不良后遗症。不幸的是,他死于急性缺氧性呼吸衰竭。这种情况突出了使用免疫疗法时必须考虑的重要考虑因素,尤其是对于已有神经系统缺陷的患者。此外,它显示出早期诊断的重要性,因为治疗可以潜在地治愈不良后遗症。不幸的是,他死于急性缺氧性呼吸衰竭。这种情况突出了使用免疫疗法时必须考虑的重要考虑因素,尤其是对于已有神经系统缺陷的患者。此外,它显示出早期诊断的重要性,因为治疗可以潜在地治愈不良后遗症。

更新日期:2020-12-28
down
wechat
bug